Fig. 4

In vivo treatment with anti-PD-L1 results in a compensatory upregulation of this marker in both Brca-deficient tumour models. Peritoneal washes (n = 5 mice per group) were collected from tumour-bearing mice that had been treated with olaparib, anti-PD-L1 or their combination, and analyzed by flow cytometry 36 h after the last treatment. Only the immune populations which are significantly different from isotype control or the combination therapy are shown. The immune populations were divided based on genotype: (A-J) for ID8 Trp53^−/− Brca1^−/− and (K-U) for Trp53^−/− Brca2.^−/− tumours. Each dot represents one biological replicate. Mean values with SEM are shown. ISO = isotype control group and OLA = olaparib treated group. One-way ANOVA with Tukey’s multiple comparison test; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001